AstraZeneca opens new manufacturing facility in Russia
Posted: 20 October 2015 |
Commercial production will begin at the new state-of-the-art site early next year and will focus on final-stage manufacturing, packaging and quality control…
AstraZeneca has opened its new state-of-the-art manufacturing and packaging facility in Kaluga, Russia, dedicated to the local supply of innovative medicines.
AstraZeneca was one of the first multinational pharmaceutical companies to announce plans to invest in the construction of a dedicated manufacturing facility in Russia in 2011. Four years on, the Company has invested $224m in the development, which is the largest foreign investment in the construction of a new pharmaceutical facility in the country.
AstraZeneca now employs more than 1,400 people in Russia working across commercial, manufacturing, scientific and clinical research and enabling functions. Around 50 of AstraZeneca’s innovative medicines are licensed for sale in Russia.
Commenting from Russia on the opening of the Kaluga facility, Pascal Soriot, Chief Executive Officer, said, “Our new dedicated production facility will support our efforts to bring innovative medicines from our exciting pipeline to patients in Russia. This opening builds on our investments in clinical research and scientific collaborations in this important country and serves to reinforce our long term commitment to Russia.”
AstraZeneca’s new site to become fully operational in 2017
Commercial production will begin early next year and will focus on final-stage manufacturing, packaging and quality control. The site will become fully operational in 2017 and will produce around 40 million packs and 850 million tablets of some 30 innovative medicines every year. This represents more than 60% of AstraZeneca’s medicines marketed in Russia to treat diseases across the Company’s therapy areas.
The new facility adds to the expansion of AstraZeneca’s global manufacturing capabilities to support the company’s expanding portfolio of medicines and growing demand, following on from the planned biologics manufacturing investments in Sweden, the acquisition of a new site in Boulder, Colorado, US, and the expansion in Frederick, Maryland, US.